PRESS RELEASE

BioNTech Congratulates CEO and Co-founder Prof. Ugur Sahin on German Cancer Award 2019

Mainz, Germany, February 28, 2019 – BioNTech AG, a rapidly growing biotechnology company developing precise and individualized immunotherapies for the treatment of cancer and the prevention of infectious diseases, congratulates its Co-founder and CEO Prof. Dr. Ugur Sahin on receiving the German Cancer Award 2019, one of the most prestigious distinctions in cancer medicine in Germany. Prof. Sahin was honored in the category Translational Research for his seminal work on individualized cancer immunotherapies and in particular the development and clinical testing of mRNA-based cancer vaccines that are tailored to each patient’s cancer mutation profile.

“As the company that was founded to advance Ugur’s research towards clinical application, we are very proud of his achievements as a leader in the cancer immunotherapy field and would like to congratulate him on this important recognition,” said Helmut Jeggle, Chairman of BioNTech’s Supervisory Board and Managing Director of the Struengmann family office. “It is a testament to his groundbreaking ideas and commitment to improving cancer treatment regimens.”

The German Cancer Award is awarded annually and honors outstanding achievements in the field of clinical oncology research, translational research and experimental research in Germany, Austria and Switzerland. This year’s ceremony was held in conjunction with the 20th international AEK Cancer Congress in Heidelberg, Germany on February 27th, 2019.

About BioNTech

BioNTech is Europe’s largest privately-held biopharmaceutical company pioneering the development of more precise and individualized therapies for cancer and the prevention of infectious diseases. The company combines all building blocks for more precise and individualized immunotherapies under one roof – from diagnostics and drug development to manufacturing. Its cutting-edge technologies range from individualized mRNA-based product candidates through innovative chimeric antigen receptors and T-cell receptor-based compounds to novel checkpoint immunomodulators and small molecules. BioNTech’s commercial approach is validated by seven corporate partnerships with Genentech, a member of the Roche Group, Pfizer, Genmab, Eli Lilly and Company, Sanofi, Genevant and Bayer Animal Health and its scientific approach through over 60 peer-reviewed scientific publications, including five publications in Nature. Founded in 2008, BioNTech’s financial shareholders include the Struengmann Family Office as its majority shareholder, Fidelity Management & Research Company, Invus, Janus Henderson Investors, MIG Fonds, Redmile Group, Salvia and several European family offices. For more information, please see: www.biontech.de

For more information, please contact:

Trophic Communications
Gretchen Schweitzer / Stephanie May
Tel: +49 (0)89 23 88 77 30 or +49 172 861 8540
Email: may@trophic.eu

US Investor Enquiries
Westwicke Partners
John Woolford
Tel: +1 (443) 213 0506
Email: john.woolford@westwicke.com